Determination of dosing regimens of erlotinib in combination with sulindac for prevention of colorectal cancer while reducing agent toxicity POP 06/01/2017 - 05/31/2019
Ended Awarded Last action
- Contract number
- HHSN26100004
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $979,494
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $979,494.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Economy Act FAR subpart 17.5
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $204,459 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $775,035 |
About this award
This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services, National Institutes of Health, National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $979,494.00, is for research to determine dosing regimens of the drug erlotinib in combination with sulindac for the prevention of colorectal cancer while reducing agent toxicity. The research is part of the NCI's Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarker studies. The contract has a period of performance from June 1, 2017 to May 31, 2019, with a final completion date of June 30, 2021. There was no set-aside designation used for this award. MD Anderson is a comprehensive cancer research and treatment center that has received numerous prime and subcontract awards from federal agencies to support cancer research initiatives.
Quick answers
Who was awarded contract HHSN26100004?
HHSN26100004 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on June 15, 2017.
How much is contract HHSN26100004 worth?
The government has obligated $979,494 on HHSN26100004.
Is contract HHSN26100004 an order under another contract?
Yes. HHSN26100004 is a delivery order under HHSN261201500018I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100004 competed?
The extent of competition for HHSN26100004 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award